ABCL vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ABCL exhibits severe financial distress according to the Piotroski F-Score (1/9), indicating weak operational and financial health. The Altman Z-Score is unavailable, but the company's negative profitability metrics—particularly a -194.88% profit margin and -14.47% ROE—highlight deep operational inefficiencies. Despite a 788.2% YoY revenue growth and strong earnings surprise history (average +30.86% over last 4 quarters), the company remains unprofitable and carries significant valuation risk. The current price of $3.49 trades at a steep 14.08 Price/Sales ratio, far exceeding sector averages, suggesting speculative pricing. Analysts' target price of $9.17 implies strong upside potential, but this is based on unproven profitability and high risk.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ABCL vs MRK: Head-to-Head Comparison
This page compares AbCellera Biologics Inc. (ABCL) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.